GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » Debt-to-EBITDA

Mankind Pharma (BOM:543904) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mankind Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Mankind Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Mankind Pharma's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹27,250 Mil. Mankind Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mankind Pharma's Debt-to-EBITDA or its related term are showing as below:

BOM:543904' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.08   Med: 0.13   Max: 0.4
Current: 0.08

During the past 3 years, the highest Debt-to-EBITDA Ratio of Mankind Pharma was 0.40. The lowest was 0.08. And the median was 0.13.

BOM:543904's Debt-to-EBITDA is ranked better than
89.04% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs BOM:543904: 0.08

Mankind Pharma Debt-to-EBITDA Historical Data

The historical data trend for Mankind Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Debt-to-EBITDA Chart

Mankind Pharma Annual Data
Trend Mar20 Mar21 Mar22
Debt-to-EBITDA
0.08 0.13 0.40

Mankind Pharma Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.09 - 0.06 -

Competitive Comparison of Mankind Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mankind Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's Debt-to-EBITDA falls into.



Mankind Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mankind Pharma's Debt-to-EBITDA for the fiscal year that ended in Mar. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8208.91 + 521.84) / 21969.99
=0.40

Mankind Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 27249.648
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Mankind Pharma  (BOM:543904) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Mankind Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mankind Pharma (BOM:543904) Business Description

Traded in Other Exchanges
Address
262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020
Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines